Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours

Summary

This document describes the guideline for peptide receptor radionuclide therapy (PRRT) published by the German Society of Nuclear Medicine (DGN) and accepted by the Association of the Scientific Medical Societies in Germany (AWMF) to be included in the official AWMF Guideline Registry. These recommendations are a prerequisite for the quality management in the treatment of patients with somatostatin receptor expressing tumours using PRRT. They are aimed at guiding nuclear medicine specialists in selecting likely candidates to receive PRRT and to deliver the treatment in a safe and effective manner. The recommendations are based on an interdisciplinary consensus. The document contains background information and definitions and covers the rationale, indications and contraindications for PRRT. Essential topics are the requirements for institutions performing the therapy, e. g. presence of an expert for medical physics, intense cooperation with all colleagues involved in the treatment of a patient, and a certificate of instruction in radiochemical labelling and quality control are required. Furthermore, it is specified which patient data have to be available prior to performance of therapy and how treatment has to be carried out technically. Here, quality control and documentation of labelling are of great importance. After treatment, clinical quality control is mandatory (work-up of therapy data and follow-up of patients). Essential elements of follow-up are specified in detail. The complete treatment inclusive after-care has to be realised in close cooperation with the involved medical disciplines. Generally, the decision for PRRT should be undertaken within the framework of a multidisciplinary tumour board.

Keywords

Neuroendocrine tumour - NET - NEN - peptide receptor radionuclide therapy - PRRT - guideline - DOTATOC - DOTATATE

^* Stand: 12/2013

^* AWMF-Registernummer: 031-045

• Literatur

• 1 Salazar R, Wiedenmann B, Rindi G, Ruszniewski P. ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: an update. Neuroendocrinology 2012; 95: 71-73.
• 2 Öberg K, Hellman P, Ferolla P, Papotti M. Group obotEGW. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: vii120-vii123.
• 3 Öberg K, Knigge U, Kwekkeboom D, Perren A. Group obotEGW. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: vii124-vii130.
• 4 Zaknun JJ, Bodei L, Mueller-Brand J. et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2013; 40: 800-816.
• 5 International Atomic Energy Agency. (Ed) Practical Guidance on Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours. www-pub.iaea.org/MTCD/Publications/PDF/P1560_web.pdf
• 6 Reubi JC, Schar JC, Waser B. et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27: 273-282.
• 7 Anlauf M, Gerlach P, Raffel A. et al. Neuroendokrine Neoplasien des gastroenteropankreatischen Systems. Der Onkologe 2011; 17: 572-582.
• 8 HÖrsch D, Grabowski P, Schneider CP. et al. Current treatment options for neuroendocrine tumors. Drugs Today (Barc) 2011; 47: 773-786.
• 9 Rinke A, Muller HH, Schade-Brittinger C. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663.
• 10 Raymond E, Dahan L, Raoul JL. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
• 11 Yao JC, Shah MH, Ito T. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
• 12 Kwekkeboom DJ, de Herder WW, Kam BL. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
• 13 Imhof A, Brunner P, Marincek N. et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [⁹⁰Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29: 2416-2423.
• 14 Bushnell Jr. DL, O'Dorisio TM, O'Dorisio MS. et al. ⁹⁰Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010; 28: 1652-1659.
• 15 Khan S, Krenning EP, van Essen M. et al. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [¹⁷⁷Lu-DOTA0,Tyr3]octreotate. J Nucl Med 2011; 52: 1361-1368.
• 16 Caplin M, Sundin A, Nillson O. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 2012; 95: 88-97.
• 17 Delle Fave G, Kwekkeboom DJ, Van Cutsem E. et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012; 95: 74-87.
• 18 Falconi M, Bartsch DK, Eriksson B. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012; 95: 120-134.
• 19 Jensen RT, Cadiot G, Brandi ML. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119.
• 20 Kwekkeboom DJ, Krenning EP, Lebtahi R. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009; 90: 220-226.
• 21 Pape UF, Perren A, Niederle B. et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95: 135-156.
• 22 Pavel M, Baudin E, Couvelard A. et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95: 157-176.
• 23 Baum RP, Kulkarni HR. THERANOSTICS: From molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy - The Bad Berka Experience. Theranostics 2012; 2: 437-447.
• 24 Kwekkeboom DJ, Teunissen JJ, Bakker WH. et al. Radiolabeled somatostatin analog [¹⁷⁷Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-2762.
• 25 Boy C, Heusner TA, Poeppel TD. et al. ⁶⁸Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging 2011; 38: 1224-1236.
• 26 Campana D, Ambrosini V, Pezzilli R. et al. Standardized uptake values of ⁶⁸Ga-DOTANOC PET: A promising prognostic tool in neuroendocrine tumors. J Nucl Med 2010; 51: 353-359.
• 27 Ezziddin S, Opitz M, Attassi M. et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2011; 38: 459-466.
• 28 Bodei L, Cremonesi M, Ferrari M. et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008; 35: 1847-1856.
• 29 Bartolomei M, Bodei L, De Cicco C. et al. Peptide receptor radionuclide therapy with ⁹⁰Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 2009; 36: 1407-1416.
• 30 Ferrari M, Cremonesi M, Bartolomei M. et al. Dosimetric model for locoregional treatments of brain tumors with ⁹⁰Y-conjugates: clinical application with ⁹⁰Y-DOTATOC. J Nucl Med 2006; 47: 105-112.
• 31 Kwekkeboom DJ, Mueller-Brand J, Paganelli G. et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005; 46 (Suppl 1) 62S-66S.
• 32 Valkema R, Pauwels SA, Kvols LK. et al. Long-term follow-up of renal function after peptide receptor radiation therapy with ⁹⁰Y-DOTA(0),Tyr(3)-octreotide and ¹⁷⁷Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005; 46 (Suppl 1) 83S-91S.
• 33 van Essen M, Krenning EP, Kam BL. et al. Report on short-term side effects of treatments with ¹⁷⁷Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35: 743-748.
• 34 Rolleman EJ, Melis M, Valkema R. et al. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010; 37: 1018-1031.
• 35 Vegt E, de Jong M, Wetzels JF. et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2010; 51: 1049-1058.
• 36 B. Braun Melsungen AG: Gelafundin 4 % InfusionslÖsung – Fachinformation. Juli 2008
• 37 Kratochwil C, Giesel FL, Lopez-Benitez R. et al. Intraindividual comparison of selective arterial versus venous ⁶⁸Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 2010; 16: 2899-2905.
• 38 Baum RP, Kulkarni HR, Carreras C. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med 2012; 42: 190-207.
• 39 Villard L, Romer A, Marincek N. et al. Cohort study of somatostatin-based radiopeptide therapy with [⁹⁰Y-DOTA]-TOC versus [⁹⁰Y-DOTA]-TOC plus [¹⁷⁷Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012; 30: 1100-1106.
• 40 Cremonesi M, Ferrari M, Bodei L. et al. Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med 2006; 47: 1467-1475.
• 41 Cremonesi M, Ferrari M, Zoboli S. et al. Biokinetics and dosimetry in patients administered with ¹¹¹In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with ⁹⁰Y-DOTATOC. Eur J Nucl Med 1999; 26: 877-886.
• 42 Kwekkeboom DJ, Bakker WH, Kooij PP. et al. [¹⁷⁷Lu-DOTAOTyr3]octreotate: comparison with [¹¹¹In-DTPAo]octreotide in patients. Eur J Nucl Med 2001; 28: 1319-1325.
• 43 Forrer F, Uusijarvi H, Waldherr C. et al. A comparison of ¹¹¹In-DOTATOC and ¹¹¹In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004; 31: 1257-1262.
• 44 Wehrmann C, Senftleben S, Zachert C. et al. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 2007; 22: 406-416.
• 45 Rodrigues M, Traub-Weidinger T, Li S. et al. Comparison of ¹¹¹In-DOTA-DPhe1-Tyr3-octreotide and ¹¹¹In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2006; 33: 532-540.
• 46 Forrer F, Krenning EP, Kooij PP. et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [¹⁷⁷Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2009; 36: 1138-1146.
• 47 Forster GJ, Engelbach MJ, Brockmann JJ. et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of ⁸⁶Y-DOTATOC and ¹¹¹In-DTPA-octreotide. Eur J Nucl Med 2001; 28: 1743-1750.
• 48 Helisch A, Forster GJ, Reber H. et al. Pre-therapeutic dosimetry and biodistribution of ⁸⁶Y-DOTA-Phe1-Tyr3-octreotide versus ¹¹¹In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004; 31: 1386-1392.
• 49 Menda Y, O'Dorisio MS, Kao S. et al. Phase I trial of ⁹⁰Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med 2010; 51: 1524-1531.
• 50 Kwekkeboom DJ, Kooij PP, Bakker WH. et al. Comparison of ¹¹¹In-DOTA-Tyr3-octreotide and ¹¹¹In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999; 40: 762-767.
• 51 Hindorf C, Chittenden S, Causer L. et al. Dosimetry for ⁹⁰Y-DOTATOC therapies in patients with neuroendocrine tumors. Cancer Biother Radiopharm 2007; 22: 130-135.
• 52 Sandstrom M, Garske U, Granberg D. et al. Individualized dosimetry in patients undergoing therapy with ¹⁷⁷Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging 2010; 37: 212-225.
• 53 Jamar F, Barone R, Mathieu I. et al. ⁸⁶Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003; 30: 510-518.
• 54 Arnold R, Chen YJ, Costa F. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009; 90: 227-233.
• 55 Ruf J, Schiefer J, Furth C. et al. ⁶⁸Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med 2011; 52: 697-704.